Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
For many patients on tirzepatide, a transformative medication used for ... and she can't afford the list price of around ...
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
12h
Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...
Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback